Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Company Overview - Day One Biopharmaceuticals is a biopharmaceutical company focused on developing and commercializing targeted therapies for life-threatening diseases across all age groups [1] - The company was founded to address the critical unmet need in pediatric cancer therapeutic development [3] - Day One aims to re-envision cancer drug development and redefine treatment possibilities for all cancer patients, inspired by "The Day One Talk" between physicians and patients [3] Pipeline and Partnerships - The company's pipeline includes tovorafenib (OJEMDA™), DAY301, and a VRK1 inhibitor program [4] - Day One collaborates with leading clinical oncologists, families, and scientists to identify, acquire, and develop targeted cancer treatments [4] Upcoming Event - Dr Jeremy Bender, CEO of Day One Biopharmaceuticals, will present at the 43rd Annual J P Morgan Healthcare Conference on January 13, 2025, at 3:45 PM Pacific Time / 6:45 PM Eastern Time [1] - A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for 30 days post-presentation [2] Corporate Information - Day One Biopharmaceuticals is headquartered in Brisbane, California [4] - The company utilizes its Investor Relations website, X handle, and LinkedIn page for disseminating business and financial information, including news, announcements, and regulatory disclosures [5]